oncolytic-virus
(3)
The Virus With a Second Job
Virogin Biotech is trying to turn an old enemy of human cells into a delivery system for cancer treatment. Its first clinical signal is intriguing; the harder test is proving that signal holds up in larger trials.
KaliVir Immunotherapeutics
KaliVir Immunotherapeutics is a clinical-stage biotech developing next-generation oncolytic viral immunotherapies for cancer. Its proprietary Vaccinia Enhanced Template (VET) platform engineers vaccinia viruses that can be delivered intravenously, replicate selectively in tumors, and express therapeutic payloads that reshape the tumor microenvironment. Founded in 2019 and headquartered in Pittsburgh, the company advances an internal lead candidate, VET3-TGI, alongside partnered programs licensed to Astellas Pharma and Roche.
Seneca Therapeutics, Inc.
Seneca Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncolytic immunotherapeutics built on SVV-001, a non-pathogenic Seneca Valley Virus that selectively replicates in solid-tumor cells expressing the TEM8/ANTXR1 receptor. Founded by oncolytic-virus pioneer Dr. Paul Hallenbeck, the company pairs SVV-001 with immune modulators and checkpoint inhibitors to spark systemic anti-tumor immunity, and is advancing a Phase I/II trial in high-grade neuroendocrine neoplasms while building a pipeline of armed and neo-antigen viral constructs.